Stay updated on Elranatamab Combo in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Combo in Myeloma Clinical Trial page.

Latest updates to the Elranatamab Combo in Myeloma Clinical Trial page
- Check3 days agoChange DetectedThe study locations list was updated with multiple new sites across the UK, New Zealand, Brazil, Austria, Belgium, and other regions, bringing the total number of locations to 127. A previously listed site at Memorial Sloan Kettering Cancer Center - Main Campus in New York was removed.SummaryDifference2%

- Check10 days agoChange DetectedThe page shows an updated revision label from v3.6.2 to v3.6.3, indicating a small maintenance update. This change does not affect the study information or how users interact with the page.SummaryDifference0.0%

- Check18 days agoChange DetectedThe Locations section was updated to include additional recruitment sites across multiple countries, and the total number of locations is shown as 121, indicating expanded geographic accessibility for the trial.SummaryDifference1%

- Check32 days agoChange DetectedThe Locations section has been expanded with numerous new study sites across several countries, increasing where participants can enroll, and the page now includes additional navigation links such as Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study.SummaryDifference3%

- Check39 days agoChange DetectedThe page now shows Revision: v3.5.5, indicating a small metadata update. Several topic tags were removed (Multiple myeloma, related topics: MedlinePlus Genetics), which appears to be a non-substantive cleanup rather than an update to trial information.SummaryDifference0.1%

- Check60 days agoChange DetectedRecruitment locations were expanded, adding numerous centers across various countries and updating the total number of locations from 39 to 89. The update includes detailed site information and current recruiting statuses to reflect broader access for potential participants.SummaryDifference7%

Stay in the know with updates to Elranatamab Combo in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Combo in Myeloma Clinical Trial page.